By Rajiv Shah* The controversy surrounding the two vaccines appears to be taking a scary turn. It so happened that I was talking to a senior healthcare expert of Gujarat on January 17. A very kind soul, this expert, whom I have known since 1990s, took the vaccine and posted the exercise on the Facebook so that others should know it's "safe". I contacted him on Facebook messenger, congratulated his gesture, and asked him which one was it. He said, "Covishield. This is the only one in Gujarat." Covishield is the name the vaccine developed by Oxford, UK, and it is being produced in the Serum Institute in Pune. It has completed all the three phases of trials. The third and final phase, which took place after enrolling around 36,000 people, I presume, in Brazil and South Africa. In sharp contrast, the other vaccine, Covaxin, a Bharat Biotech product, hasn't yet completed its third trial, yet it has been "approved" by the Government of India. The health